Triple
T22717595
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Genzyme |
E561775
|
entity |
| Predicate | hasProduct |
P3585
|
FINISHED |
| Object | Thymoglobulin |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Thymoglobulin | Statement: [Genzyme, hasProduct, Thymoglobulin]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Thymoglobulin Context triple: [Genzyme, hasProduct, Thymoglobulin]
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Ofatumumab
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
-
C.
mycophenolate mofetil
Mycophenolate mofetil is an immunosuppressive medication commonly used to prevent organ transplant rejection and to treat various autoimmune diseases.
-
D.
cyclosporine A
Cyclosporine A is an immunosuppressant drug widely used to prevent organ transplant rejection and treat certain autoimmune diseases.
-
E.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Thymoglobulin Target entity description: Thymoglobulin is an immunosuppressive anti-thymocyte globulin used primarily to prevent and treat acute rejection in organ transplantation.
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Ofatumumab
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
-
C.
mycophenolate mofetil
Mycophenolate mofetil is an immunosuppressive medication commonly used to prevent organ transplant rejection and to treat various autoimmune diseases.
-
D.
cyclosporine A
Cyclosporine A is an immunosuppressant drug widely used to prevent organ transplant rejection and treat certain autoimmune diseases.
-
E.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454fc984819088213b58ee87a002 |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1790ecbc48190926d16b20b674dbd |
completed | April 29, 2026, 3:20 a.m. |
Created at: April 17, 2026, 3:19 p.m.